Drug Trial Radar · NCT00070278
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 7, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
800
Planned (sponsor's estimate)
Start
Jan 2005
Primary completion
Sep 2007
Sponsor
- Lead sponsor
- Cambridge University Hospitals NHS Foundation TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 7, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, paclitaxel, and gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy before surgery may shrink the tumor so that it can be removed during surgery. It is not yet known which combination chemotherapy regimen is more effective in treating early breast cancer. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating women who are undergoing surgery for early invasive breast cancer.
Conditions
- Breast Cancer
Interventions
cyclophosphamideDrug
epirubicin hydrochlorideDrug
gemcitabine hydrochlorideDrug
paclitaxelDrug
comparative genomic hybridizationGenetic
microarray analysisGenetic
mutation analysisGenetic
conventional surgeryProcedure
neoadjuvant therapyProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete pathological response after 4 courses
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust
Cambridge, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.